ALERE NMP22 BLADDERCHECK TEST & CONTROL KIT

System, Test, Tumor Marker, For Detection Of Bladder Cancer

FDA Premarket Approval P940035 S008

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Approval for the intent to manufacture the nmp22 bladderchek test and nmp22 bladderchek control kit under alere scarborough, inc. Brand name. The devices, as modified, will be marketed under the following trade name: alere nmp22 bladderchek test, with the following intended use: the alere nmp22 bladderchek test is an in vitro immunoassay intended for the qualitative detection of the nuclear mitotic apparatus protein (numa), which is an abundant component of the nuclear matrix proteins, in urine of persons with risk factors or symptoms of bladder cancer or with a history of bladder cancer. This test is indicated for professional use and prescription home use as an aid in diagnosing and monitoring bladder cancer patients, in conjunction with standard diagnostic procedures. Alere nmp22 bladderchek control kit, with the following intended use: alere nmp22 bladderchek control kit is designed to provide the users of the alere nmp22 bladderchek test with additional, optional, quality controls for operating the test.

DeviceALERE NMP22 BLADDERCHECK TEST & CONTROL KIT
Classification NameSystem, Test, Tumor Marker, For Detection Of Bladder Cancer
Generic NameSystem, Test, Tumor Marker, For Detection Of Bladder Cancer
ApplicantALERE SCARBOROUGH, INC
Date Received2010-11-22
Decision Date2012-03-21
PMAP940035
SupplementS008
Product CodeNAH
Advisory CommitteeImmunology
Supplement TypeNormal 180 Day Track No User Fee
Supplement ReasonLabeling Change - Indications/instructions/shelf Life/tradename
Expedited ReviewNo
Combination Product No
Applicant Address ALERE SCARBOROUGH, INC 10 Southgate Road scarborough, ME 04074

Supplemental Filings

Supplement NumberDateSupplement Type
P940035Original Filing
S017 2022-02-08 Normal 180 Day Track No User Fee
S016 2021-05-27 30-day Notice
S015 2018-04-18 30-day Notice
S014 2017-01-30 30-day Notice
S013 2016-08-16 30-day Notice
S012 2016-04-06 30-day Notice
S011 2015-07-01 30-day Notice
S010 2013-07-10 Special (immediate Track)
S009 2013-03-18 30-day Notice
S008 2010-11-22 Normal 180 Day Track No User Fee
S007 2011-07-27 Normal 180 Day Track No User Fee
S006 2011-05-11 Normal 180 Day Track No User Fee
S005 2008-05-16 Normal 180 Day Track No User Fee
S004 2008-03-27 Normal 180 Day Track No User Fee
S003 2002-09-16 Normal 180 Day Track
S002 1999-07-23 Panel Track
S001 1996-12-16 Normal 180 Day Track

NIH GUDID Devices

Device IDPMASupp
10811877010637 P940035 000
10811877010545 P940035 000

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.